LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumo… Read more
LadRx Corporation (LADX) - Net Assets
Latest net assets as of March 2025: $-2.13 Million USD
Based on the latest financial reports, LadRx Corporation (LADX) has net assets worth $-2.13 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($260.07K) and total liabilities ($2.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.13 Million |
| % of Total Assets | -820.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -116.0% |
| 10-Year Change | N/A |
| Growth Volatility | 555.06 |
LadRx Corporation - Net Assets Trend (2018–2024)
This chart illustrates how LadRx Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LadRx Corporation (2018–2024)
The table below shows the annual net assets of LadRx Corporation from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.42 Million | -1422.19% |
| 2023-12-31 | $107.35K | +317.40% |
| 2022-12-31 | $25.72K | -99.46% |
| 2021-12-31 | $4.78 Million | -46.16% |
| 2020-12-31 | $8.87 Million | -41.66% |
| 2019-12-31 | $15.20 Million | -25.33% |
| 2018-12-31 | $20.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LadRx Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3323163100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $488.68 Million | % |
| Total Equity | $-1.42 Million | 100.00% |
LadRx Corporation Competitors by Market Cap
The table below lists competitors of LadRx Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daios Plastics S.A.
AT:DAIOS
|
$49.51K |
|
Tatton Asset Management plc
LSE:TAM
|
$49.53K |
|
Magnum Goldcorp Inc
PINK:MGIDF
|
$49.56K |
|
Custodian REIT PLC
LSE:CREI
|
$49.58K |
|
House of Jane Inc
PINK:HOJI
|
$49.47K |
|
EUROPEAN MEDICAL SOLUTIONS
BR:ALEMS
|
$49.45K |
|
DENNY'S
BE:DE8
|
$49.41K |
|
WEWORK INDIA MANAGEMENT L
NSE:WEWORK
|
$49.40K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LadRx Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 107,354 to -1,419,429, a change of -1,526,783 (-1422.2%).
- Net loss of 1,589,685 reduced equity.
- Other factors increased equity by 62,902.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.59 Million | -111.99% |
| Other Changes | $62.90K | +4.43% |
| Total Change | $- | -1422.19% |
Book Value vs Market Value Analysis
This analysis compares LadRx Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.61 | $1.28 | x |
| 2019-12-31 | $0.45 | $1.28 | x |
| 2020-12-31 | $0.24 | $1.28 | x |
| 2021-12-31 | $0.12 | $1.28 | x |
| 2022-12-31 | $0.00 | $1.28 | x |
| 2023-12-31 | $0.22 | $1.28 | x |
| 2024-12-31 | $-2.87 | $1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LadRx Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2345.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -62.44% | -5085.44% | 0.01x | 1.13x | $-14.75 Million |
| 2019 | -47.11% | 0.00% | 0.00x | 1.13x | $-8.68 Million |
| 2020 | -75.53% | 0.00% | 0.00x | 1.36x | $-7.59 Million |
| 2021 | -275.87% | 0.00% | 0.00x | 1.83x | $-13.65 Million |
| 2022 | -16331.93% | 0.00% | 0.00x | 87.36x | $-4.20 Million |
| 2023 | 373.01% | 0.00% | 0.00x | 21.50x | $389.71K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.45 Million |
Industry Comparison
This section compares LadRx Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LadRx Corporation (LADX) | $-2.13 Million | -62.44% | N/A | $49.51K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |